An interventional Study on selective siddha medicines like seenthil chooranam, inji rasayanam, mandurathi kudineer in the management of kaleeral noi(Alcoholic Liver Disease stage I and stage II)

An open clinical trial to evaluate the effectiveness of selective siddha medicines in the management of kaleeral noi (Alcoholic Liver Disease stage I and stage II) among out patients attending ayothidoss pandithar hospital national institute of siddha - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/079854

Enrollment

Registered

2025-02-03

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K700- Alcoholic fatty liver

Interventions

Intervention1: Seenthil chooranam Inji rasayanam Mandurathi kudineer: Seenthil chooranam 2g twice a Day with ghee for 48 days Inji rasayanam 6g twice a day with warm water for 48 days Mandurathi kud

Eligibility

Inclusion criteria

Inclusion criteria: Age group: 30-65 years Gender: All gender Patient has the history of alcoholic more than 5yrs and who are Alcohol abstinence with ALD included. Patient having CIWA-Ar scale less than 19 (mild to moderate) Patient having MDF score less than 32 (mild to moderate)

Exclusion criteria

Exclusion criteria: Pregnancy or lactation Fasting glucose levels greater than 250 mg per decilitre Concomitant disease with reduced life expectancy Hepatic failure Severe psychiatric conditions Drug dependence Patients with known liver diseases such as viral hepatitis, non alcoholic fatty liver, autoimmune disorders, biliary disorder, liver abscess, cirrhosis and malignancy

Design outcomes

Primary

Measure	Time frame
PRIMARY OUTCOME: Reduction in signs and symptoms of alcoholic liver disease will be assessed before and after treatment.Timepoint: PRIMARY OUTCOME: Reduction in signs and symptoms of alcoholic liver disease will be assessed before and after treatment. SECONDARY OUTCOME: Changes in Lipid Profile, MDF Score,Fasting Blood Sugar and Liver Function Test will be assessed before and after treatment Changes in ultrasonography of abdomen(liver) Changes in waist circumference and Body Mass Index will be assessed before and after treatment	—

Measure

Time frame

PRIMARY OUTCOME: Reduction in signs and symptoms of alcoholic liver disease will be assessed before and after treatment.Timepoint: PRIMARY OUTCOME: Reduction in signs and symptoms of alcoholic liver disease will be assessed before and after treatment. SECONDARY OUTCOME: Changes in Lipid Profile, MDF Score,Fasting Blood Sugar and Liver Function Test will be assessed before and after treatment Changes in ultrasonography of abdomen(liver) Changes in waist circumference and Body Mass Index will be assessed before and after treatment

—

Secondary

Measure	Time frame
SECONDARY OUTCOME: Changes in Lipid Profile, MDF Score,Fasting Blood Sugar and Liver Function Test will be assessed before and after treatment Changes in ultrasonography of abdomen(liver) Changes in waist circumference and Body Mass Index will be assessed before and after treatmentTimepoint:	—

Countries

India

Contacts

Public ContactDr V Manjari

National Institute of Siddha

drmanjarimd@gmail.com8056903083

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026